DK2292227T3 - Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity - Google Patents

Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity Download PDF

Info

Publication number
DK2292227T3
DK2292227T3 DK10011181.4T DK10011181T DK2292227T3 DK 2292227 T3 DK2292227 T3 DK 2292227T3 DK 10011181 T DK10011181 T DK 10011181T DK 2292227 T3 DK2292227 T3 DK 2292227T3
Authority
DK
Denmark
Prior art keywords
compounds
alkyl
hgf
alkoxy
compound
Prior art date
Application number
DK10011181.4T
Other languages
Danish (da)
English (en)
Inventor
David E Zembower
David Einzhamer
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Application granted granted Critical
Publication of DK2292227T3 publication Critical patent/DK2292227T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK10011181.4T 2002-12-21 2003-12-19 Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity DK2292227T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43553302P 2002-12-21 2002-12-21
US10/740,708 US7192976B2 (en) 2002-12-21 2003-12-18 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP03814306.1A EP1572199B1 (en) 2002-12-21 2003-12-19 Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity

Publications (1)

Publication Number Publication Date
DK2292227T3 true DK2292227T3 (en) 2016-12-19

Family

ID=32685400

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03814306.1T DK1572199T3 (da) 2002-12-21 2003-12-19 Pyrazol-derivater som modulatorer af hepatocyt-vækst-faktor (scatter factor) aktivitet
DK10011181.4T DK2292227T3 (en) 2002-12-21 2003-12-19 Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03814306.1T DK1572199T3 (da) 2002-12-21 2003-12-19 Pyrazol-derivater som modulatorer af hepatocyt-vækst-faktor (scatter factor) aktivitet

Country Status (10)

Country Link
US (6) US7192976B2 (enExample)
EP (2) EP1572199B1 (enExample)
JP (3) JP5160019B2 (enExample)
CN (1) CN1747730B (enExample)
AU (1) AU2003301224C1 (enExample)
CA (1) CA2511199C (enExample)
DK (2) DK1572199T3 (enExample)
HU (1) HUE030700T2 (enExample)
IL (1) IL169316A (enExample)
WO (1) WO2004058721A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US7879898B1 (en) 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
CN102149379A (zh) * 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
US20110237633A1 (en) * 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2493495A4 (en) * 2009-07-10 2013-08-21 Univ Northwestern HERZSCHÜTZENDE ROLE OF LIVER CELLS AND SEKRETORIC FACTORS FROM LIVER CELLS IN MYOCARDIAN EMERGENCE
WO2011019400A2 (en) * 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity
RU2017144535A (ru) * 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
US20130190376A1 (en) * 2010-10-05 2013-07-25 David E. Smith Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
JP6173298B2 (ja) 2011-04-02 2017-08-02 ワシントン ステート ユニバーシティ 治療薬としての肝細胞増殖因子模倣体
WO2012151349A1 (en) 2011-05-03 2012-11-08 Liu Shu Q Neuroprotection by hepatic cells and hepatocyte secretory factors
UY34200A (es) * 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
BR112015023214A8 (pt) 2013-03-15 2019-12-24 Verseon Corp composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
PL2968297T3 (pl) 2013-03-15 2019-04-30 Verseon Corp Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej
EP3194369A4 (en) 2014-09-17 2018-02-28 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2977993A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CA3133803A1 (en) 2019-04-11 2020-10-15 Angion Biomedica Corp. Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
US20230000828A1 (en) * 2019-10-31 2023-01-05 Angion Biomedica Corp. Improving renal function after kidney transplantation
WO2021183774A1 (en) * 2020-03-12 2021-09-16 Angion Biomedica Corp. Treating acute respiratory distress
WO2022081703A2 (en) * 2020-10-14 2022-04-21 Angion Biomedica Corp. Preparation of terevalefim and formulations thereof
CN119684295A (zh) * 2020-11-02 2025-03-25 雅斯娜制药公司 用于治疗疾病的双环化合物及其用途
WO2022217070A1 (en) * 2021-04-09 2022-10-13 Angion Biomedica Corp. Hgf/sf mimetic compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138770C (enExample) *
JPS48713Y1 (enExample) 1967-12-19 1973-01-09
JPS48713U (enExample) 1971-05-22 1973-01-08
DD138770A1 (de) * 1978-09-20 1979-11-21 Juergen Liebscher Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen
JPH02193994A (ja) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd ピリダジノン誘導体
FR2669633B1 (fr) * 1990-11-23 1993-01-22 Adir Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5476076A (en) * 1994-12-06 1995-12-19 Zhou; Zhishan Internal combustion piston engine utilizing interference movable fit technology
JPH11288112A (ja) 1998-04-06 1999-10-19 Mitsubishi Paper Mills Ltd 電子写真感光体
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7459536B1 (en) * 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
EP1355921A2 (en) 2000-06-29 2003-10-29 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
AU2002313690A1 (en) 2002-07-19 2004-02-09 Targacept, Inc. Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity

Also Published As

Publication number Publication date
AU2003301224C1 (en) 2011-09-22
WO2004058721A3 (en) 2004-10-28
DK1572199T3 (da) 2014-02-03
US7265112B2 (en) 2007-09-04
US20050113369A1 (en) 2005-05-26
IL169316A0 (en) 2007-07-04
US20140256780A1 (en) 2014-09-11
CA2511199A1 (en) 2004-07-15
US20190382348A1 (en) 2019-12-19
HUE030700T2 (en) 2017-05-29
JP2010265322A (ja) 2010-11-25
JP5755417B2 (ja) 2015-07-29
EP1572199A2 (en) 2005-09-14
CN1747730A (zh) 2006-03-15
EP1572199B1 (en) 2013-11-20
US7192976B2 (en) 2007-03-20
WO2004058721A2 (en) 2004-07-15
CN1747730B (zh) 2013-05-29
AU2003301224A1 (en) 2004-07-22
US7250437B2 (en) 2007-07-31
US9663471B2 (en) 2017-05-30
JP5160019B2 (ja) 2013-03-13
US20050192331A1 (en) 2005-09-01
US20080015243A1 (en) 2008-01-17
US8580834B2 (en) 2013-11-12
CA2511199C (en) 2014-02-11
JP2006513221A (ja) 2006-04-20
JP2015078246A (ja) 2015-04-23
EP2292227A2 (en) 2011-03-09
HK1085651A1 (en) 2006-09-01
EP2292227A3 (en) 2011-05-25
US20040180882A1 (en) 2004-09-16
IL169316A (en) 2013-09-30
EP2292227B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
US9663471B2 (en) Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity
AU2003301224B2 (en) Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity
US20110237633A1 (en) Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US10899750B2 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
CA2579240A1 (en) Small molecule modulators of cytokine activity
CA2813719A1 (en) Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
HK1085651B (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity